CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Lysogene SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Lysogene SA
18-20 rue Jacques Dulud
Phone: +33 141430390p:+33 141430390 NEUILLY-SUR-SEINE, 92200  France Fax: +33 141430363f:+33 141430363
Filed for Bankruptcy on 5/26/2023
On 12/6/2022, Lysogene SA filed an application for Safeguard Proceedings with the Commercial Court of Nanterre. Helene Bourboulou of SELARL FHB was appointed as the Administrator of the Company, with Gurvan Ollu as the Judicial Representative
On 1/24/2023, the Commercial Court of Nanterre converted Lysogene SA's Safeguard Proceedings to one of Reorganization pursuant to the Company's request.
On 5/26/2023, the Commercial Court of Nanterre announced its decision to convert the reorganization proceedings into liquidation proceedings.
This company is no longer actively traded on any major stock exchange.
Business Summary
Lysogene SA is a France-based company principally engaged in the bio diagnostics and testing. The Company is focused on the gene therapy biotechnology. The Company develops treatments targeting severe genetic pathologies with central nervous system involvement and high unmet medical needs. It is specialized in the development of intracerebral gene therapy aimed at treating pathologies affecting the central nervous system, which is the main cause of neuro-degenerative disease mortality in children.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202212/31/2021Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Founder KarenAiach 50 5/22/2019
Chief Financial Officer Comede La Tour Du Pin 2/3/2023 2/3/2023
Chief Technical Officer MarkPlavsic
10 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 17,797,984 (As of 6/30/2022)
Stock Exchange: EPA
Fax Number: +33 141430363


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, March 26, 2024